( r mini-stroke but no known coronary hea...)Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke,Health

r mini-stroke but no known coronary heart disease. In these patients, Lipitor significantly reduced the risk of coronary heart disease events by 43 percent compared with those taking placebo. The risk of stroke was reduced by 12 percent and major coronary events by 26 percent, but these results were not statistically significant.

"This analysis reminds us of the importance of managing patients' overall risk factors to reduce the risk of serious complications," said Dr. Welch.

About the SPARCL Study

The SPARCL study, published in the New England Journal of Medicine in 2006, is the only study to date evaluating statin therapy exclusively for patients with recent stroke or mini-stroke and no coronary heart disease (n=4,731). Lipitor 80 mg is the only statin to have shown stroke benefit in these patients. Lipitor 80 mg reduced the risk of an additional stroke by 16 percent and major coronary events by 35 percent compared with placebo. In a post-hoc analysis of the SPARCL trial, there was a higher incidence of hemorrhagic stroke in patients taking Lipitor 80 mg compared with patients taking placebo. Patients with prior hemorrhagic stroke at study entry appeared to be at an increased risk of hemorrhagic stroke.

In SPARCL, Lipitor was well tolerated. The rate of side effects such as elevated liver enzymes was low and consistent with the known safety profile and there was no difference in the incidence of muscle weakness or rhabdomyolysis between groups. Lipitor 80 mg is not a starting dose.

About Lipitor

Lipitor is extensively studied and the most prescribed cholesterol-lowering therapy in the world, with nearly 139 million patient-years of experience. Lipitor is supported by an extensive clinical trial program involving more than 400 ongoing and completed trials with more than 80,000 patients.

Important Safety Information

Lipitor is a prescription medication. It is used in patients with multiple risk factors for hear
'"/>

Page: 1 2 3
Related medicine technology :

1. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
2. Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
3. Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
6. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat